Patents by Inventor Gary R. Gustafson

Gary R. Gustafson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180183380
    Abstract: The present invention is an apparatus and method using solar insolation to heat fluid moving through panels, resulting in relatively hot fluid. A set of such panels might be installed in a window. Heat is removed from the hot fluid in a heat reservoir or heat sink, resulting in relatively cool fluid. In some embodiments, the hot fluid and the cool fluid are placed in thermal contact with opposite sides of a thermoelectric generator, thereby generating electricity. In some embodiments, photovoltaic cell modules are embedded in the panels, the fluid system improving the effectiveness of the cells. A given system might use either approach to generate electricity, or both. Heat from the heat reservoir might be used to heat a building. A thermoelectric system might be run in reverse at night.
    Type: Application
    Filed: June 9, 2016
    Publication date: June 28, 2018
    Inventor: Gary R. Gustafson
  • Publication number: 20170174658
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 22, 2017
    Inventors: Jian LIN, Anna ERICSSON, Ann-Marie CAMPBELL, Gary R. GUSTAFSON, Zhongguo WANG, R. Bruce DIEBOLD, Susan ASHWELL, David LANCIA, JR., Justin Andrew CARAVELLA, Wei LU
  • Patent number: 8835422
    Abstract: The present invention provides substituted imidazoheterocycles having the general structure of formula I: wherein Y is chosen from —O—, —OCRgRh—, —CRgRhO—, —CRgRh—, —(CRgRh)2—, —NRi—, —CRgRhNRi— and —NRiCRgRh—. Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: September 16, 2014
    Assignee: Cara Therapeutics, Inc.
    Inventors: Stephen J. O'Connor, Jason S. Newcom, Janet L. Ralbovsky, Gary R. Gustafson, R. Paul Beckett, Robert Zhiyong Luo
  • Patent number: 8650877
    Abstract: The present invention is a solar panel that generates electricity and extracts heat. A set of such panels may be assembled into a blind. The blind may have a frame that can be retrofit on an existing window. Fluid in the panel is heated by incoming solar radiation, causing it to move, constrained by a one-way valve, in one direction. A Tesla Valve may be used as the one-way valve. The moving fluid may pass through a generator, generating electricity. Heat may be extracted from the fluid by a heat exchanger. The heat may be used to heat a building.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 18, 2014
    Inventor: Gary R. Gustafson
  • Patent number: 8431565
    Abstract: The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: April 30, 2013
    Assignee: Cara Therapeutics, Inc.
    Inventors: R. Paul Beckett, Richard Foster, Christelle Henault, Janet L. Ralbovsky, Carla M. Gauss, Gary R. Gustafson, Robert Zhiyong Luo, Ann-Marie Campbell, Tatiana E. Shelekhin, Mary-Margaret E. Zablocki
  • Publication number: 20120015930
    Abstract: The present invention provides substituted imidazoheterocycles having the general structure of formula I: wherein Y is chosen from —O—, —OCRgRh—, —CRgRhO—, —CRgRh—, —(CRgRh)2—, —NRi—, —CRgRhNRi— and —NRiCRgRh—. Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    Type: Application
    Filed: December 1, 2009
    Publication date: January 19, 2012
    Applicant: CARA THERAPEUTICS, INC.
    Inventors: Stephen J. O'Connor, Jason S. Newcom, Janet L. Ralbovsky, Gary R. Gustafson, R. Paul Beckett, Robert Zhiyong Luo
  • Patent number: 7960377
    Abstract: The invention provides compounds having the structure of formula I, and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R1, R2, R3 and R4 are defined in the specification. These compounds can be administered in pharmaceutical formulations to modulate cannabinoid receptor activity for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: June 14, 2011
    Assignee: Cara Therapeutics, Inc.
    Inventors: Jason S. Newcom, Stephen J. O'Connor, Gary R. Gustafson
  • Patent number: 7960376
    Abstract: The present invention provides benzo-fused heterocyclic compounds having the structure of formula I, as well as prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof. The compounds directly or indirectly modulate the activity of one or more cannabinoid receptors and can be incorporated into pharmaceutical preparations that are useful for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: June 14, 2011
    Assignee: Cara Therapeutics, Inc.
    Inventors: Jason S. Newcom, Carla M. Gauss, Gary R. Gustafson
  • Publication number: 20090247502
    Abstract: The invention provides compounds having the structure of formula I, and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R1, R2, R3 and R4 are defined in the specification. These compounds can be administered in pharmaceutical formulations to modulate cannabinoid receptor activity for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.
    Type: Application
    Filed: March 24, 2009
    Publication date: October 1, 2009
    Applicant: CARA THERAPEUTICS, INC.
    Inventors: Jason S. Newcom, Stephen J. O'Connor, Gary R. Gustafson
  • Publication number: 20090149450
    Abstract: The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    Type: Application
    Filed: December 18, 2008
    Publication date: June 11, 2009
    Applicant: CARA THERAPEUTICS, INC.
    Inventors: R. Paul Beckett, Richard Foster, Christelle Henault, Janet L. Ralbovsky, Carla M. Gauss, Gary R. Gustafson, Robert Zhiyong Luo, Ann-Marie Campbell, Tatiana E. Shelekhin, Mary-Margaret E. Zablocki
  • Publication number: 20090075973
    Abstract: The present invention provides benzo-fused heterocyclic compounds having the structure of formula I, as well as prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof. The compounds directly or indirectly modulate the activity of one or more cannabinoid receptors and can be incorporated into pharmaceutical preparations that are useful for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.
    Type: Application
    Filed: September 10, 2008
    Publication date: March 19, 2009
    Applicant: CARA THERAPEUTICS, INC.
    Inventors: Jason S. Newcom, Carla M. Gauss, Gary R. Gustafson
  • Publication number: 20080318935
    Abstract: The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    Type: Application
    Filed: June 20, 2008
    Publication date: December 25, 2008
    Applicant: CARA THERAPEUTICS, INC.
    Inventors: R. Paul Beckett, Richard Foster, Christelle Henault, Janet L. Ralbovsky, Carla M. Gauss, Gary R. Gustafson, Zhiyong Luo, Ann-Marie Campbell, Tatiana E. Shelekhin
  • Publication number: 20080161340
    Abstract: Tetrahydroquinolinone and tetrahydronaphthyridone cannabinoid receptor ligand compounds and stereoisomers, mixtures of stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, acid salt hydrates, and isomorphic crystalline forms thereof are described.
    Type: Application
    Filed: December 19, 2007
    Publication date: July 3, 2008
    Applicant: CARA THERAPEUTICS, INC.
    Inventors: Gary R. Gustafson, R. Paul Beckett
  • Patent number: 7307079
    Abstract: The invention relates to a group of novel triazine derivatives which are ligands for human adenosine-A3 receptors, as well as to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient. The invention relates to compounds of the general formula (1) wherein Y represents a group of the general formula (A), (B) or (C) and all other symbols have the meanings as given in the description.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: December 11, 2007
    Assignees: Solvay Pharmaceuticals, B.V., Arqule, Inc.
    Inventors: Jacobus A.J. Den Hartog, Jan H. Reinders, Guustaaf J.M. Van Scharrenburg, Maria L. Pras-Raves, Gary R. Gustafson
  • Publication number: 20040038972
    Abstract: The invention relates to a group of novel triazine derivatives which are ligands for human adenosine-A3 receptors, as well as to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient.
    Type: Application
    Filed: May 30, 2003
    Publication date: February 26, 2004
    Inventors: Jacobus A.J. Den Hartog, Jan H. Reinders, Guustaaf J.M. Van Scharrenburg, Maria L. Pras-Raves, Gary R. Gustafson
  • Publication number: 20020052295
    Abstract: Novel herbicidal compounds are provided having the formula (I) 1
    Type: Application
    Filed: December 5, 2000
    Publication date: May 2, 2002
    Inventors: Shridhar G. Hegde, Daniel M. Krupa, Joseph A. Bohn, David L. Coffen, Gary R. Gustafson, Alan P. Kaplan, Yuting Ma
  • Patent number: 6239291
    Abstract: The present invention provides convergent processes for preparing myxopyronins and corallopyronins, compounds useful as antibacterial therapeutics. The present invention also provides novel compositions of matter which are useful for the preparation of pyronin antibiotics.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: May 29, 2001
    Assignees: Scriptgen Pharmaceuticals, Inc., Trustees of Boston University
    Inventors: Mark A. Wuonola, Gary R. Gustafson, James S. Panek, Tao Hu, Jennifer V. Schaus
  • Patent number: 6228882
    Abstract: The present invention provides convergent processes for preparing myxopyronins and corallopyronins, compounds useful as antibacterial therapeutics. The present invention also provides novel compositions of matter which are useful for the preparation of pyronin antibiotics.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: May 8, 2001
    Assignees: Anadys Pharmaceuticals, Inc., Scriptgen Pharmaceuticals, Inc.
    Inventors: Mark A. Wuonola, Gary R. Gustafson, James S. Panek, Tao Hu, Jennifer V. Schaus
  • Patent number: 6184393
    Abstract: The present invention provides convergent processes for preparing myxopyronins and corallopyronins, compounds useful as antibacterial therapeutics. The present invention also provides novel compositions of matter which are useful for the preparation of pyronin antibiotics.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: February 6, 2001
    Assignees: Trustees of Boston University, Scriptgen Pharmaceuticals, Inc.
    Inventors: Mark A. Wuonola, Gary R. Gustafson, James S. Panek, Tao Hu, Jennifer V. Schaus
  • Patent number: 6140361
    Abstract: 2-Deoxystreptamine is an aminocyclitol whose structural stability and abundant functionality make it an attractive scaffold for the combinatorial generation of small molecules. The ability to selectively functionalize the various positions of 2-deoxystreptamine with an almost infinite number of different groups ensures that the libraries so generated will be both spatially and functionally diverse. These compounds can then be screened for biological activity to afford lead compounds for pharmaceutical programs. Additionally, biological ligand mimics based on 2-deoxystreptamine can be readily appended, either directly or through a tether, to solid surfaces or incorporated covalently into gels to afford novel materials useful in separation science.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: October 31, 2000
    Assignee: Scriptgen Pharmaceuticals, Inc.
    Inventors: Gary R. Gustafson, David G. Powers, Mark A. Wuonola